SequelSEC

Amylyx Pharmaceuticals, Inc. AMLX

Pharmaceutical Preparations · CIK 0001658551 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2025-12-31
Operating income
-$153.29M
Fiscal year ended 2025-12-31
Free cash flow
-$123.48M
Fiscal year ended 2025-12-31

Amylyx Pharmaceuticals, Inc. (AMLX) reported revenue of $0 and net income of -$144.74M for the fiscal year ended 2025-12-31. This page shows 5 annual periods of income statement, balance sheet and cash flow figures normalized from Amylyx Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Amylyx Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue$0$87.37M$380.79M$22.23M$285.00K
Cost of revenue$0$5.95M$25.44M$2.99MUnavailable
Gross profit$0$81.42M$355.34M$19.24MUnavailable
Operating income-$153.29M-$314.73M$38.80M-$201.34M-$82.69M
Net income-$144.74M-$301.74M$49.27M-$198.38M-$87.93M
Research & development$90.40M$104.08M$128.19M$93.45M$44.04M
Weighted-average diluted sharesshares 94.57Mshares 68.14Mshares 69.99Mshares 58.50Mshares 6.59M
Pretax income-$144.69M-$302.14M$54.30M-$197.60M-$87.93M
Income tax expense$46.00K-$393.00K$5.03M$774.00KUnavailable
Diluted EPS$-1.53$-4.43$0.70$-3.39$-13.35
Selling, general & administrative$62.89M$114.33M$188.36M$127.13M$38.93M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Amylyx Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-31
Cash & equivalents$226.65M$77.39M$170.20M$62.53M$50.19M
Total assets$332.64M$193.63M$517.45M$391.45M$105.61M
Current assets$323.67M$189.43M$464.67M$382.13M$104.95M
Total liabilities$27.39M$28.87M$84.02M$50.85M$17.43M
Current liabilities$22.69M$28.41M$82.04M$46.61M$17.40M
Total equity incl. NCI$305.26M$164.76M$433.43M$340.61M-$151.17M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable$239.35M
InventoryUnavailableUnavailable$38.32M$9.77MUnavailable
Accounts receivable$88.00K$447.00K$40.05M$15.31MUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.52M$2.94M$22.06M$6.26M$4.37M

Cash flow

Amylyx Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-31
Operating cash flow-$123.34M-$167.65M$11.92M-$179.87M-$74.80M
Capital expenditures$138.00K$157.00K$1.24M$2.53M$353.00K
Investing cash flow$14.04M$75.65M$92.05M-$238.99M-$46.41M
Financing cash flow$257.03M$348.00K$3.54M$431.79M$158.51M
Net change in cash$148.80M-$92.08M$107.68M$12.86M$37.31M
Stock-based compensation$27.64M$33.04M$37.16M$21.71M$3.14M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Amylyx Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-31
Free cash flow-$123.48M-$167.80M$10.68M-$182.40M-$75.15M
Gross marginUnavailable93.2%93.3%86.5%Unavailable
Operating marginUnavailable-360.2%10.2%-905.7%-29013.3%
FCF marginUnavailable-192.1%2.8%-820.5%-26369.1%
SBC / revenueUnavailable37.8%9.8%97.7%1100.4%
Current ratio14.27x6.67x5.66x8.20x6.03x
Revenue YoY growth-100.0%-77.1%1612.9%7700.0%Unavailable
Net marginUnavailable-345.4%12.9%-892.4%-30853.0%
R&D / revenueUnavailable119.1%33.7%420.4%15452.6%
CapEx / revenueUnavailable0.2%0.3%11.4%123.9%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailable9.3%UnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AMLX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-03View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.